Isabelle Gilloteau
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Journal: Clinical lung cancer
Published: February 28, 2023
Understanding the patient experience and treatment benefits in patients with non-small-cell lung cancer with brain metastasis.
Journal: Cancer medicine
Published: December 22, 2022
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 23, 2022
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial.
Journal: The Lancet. Rheumatology
Published: August 13, 2021
Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany.
Journal: The Journal of dermatological treatment
Published: February 04, 2021
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
Journal: Arthritis care & research
Published: October 11, 2019
Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials.
Journal: Acta dermato-venereologica
Published: April 25, 2019
Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.
Journal: Journal of medical economics
Published: October 06, 2018
Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK.
Journal: The Journal of dermatological treatment
Published: September 27, 2018
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Journal: Journal of the American Academy of Dermatology
Published: August 29, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Journal: Dermatology and therapy
Published: August 28, 2018
Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.
Journal: Journal of the American Academy of Dermatology
Published: July 26, 2018
Last Updated: 09/26/2026